Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Si-Hyun | - |
dc.contributor.author | Kwon, Jae-Cheol | - |
dc.contributor.author | Choi, Su-Mi | - |
dc.contributor.author | Lee, Dong-Gun | - |
dc.contributor.author | Park, Sun Hee | - |
dc.contributor.author | Choi, Jung-Hyun | - |
dc.contributor.author | Yoo, Jin-Hong | - |
dc.contributor.author | Cho, Byung-Sik | - |
dc.contributor.author | Eom, Ki-Seong | - |
dc.contributor.author | Kim, Yoo-Jin | - |
dc.contributor.author | Kim, Hee-Je | - |
dc.contributor.author | Lee, Seok | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Cho, Seok-Goo | - |
dc.contributor.author | Kim, Dong-Wook | - |
dc.contributor.author | Lee, Jong-Wook | - |
dc.contributor.author | Min, Woo-Sung | - |
dc.date.accessioned | 2021-09-06T02:54:04Z | - |
dc.date.available | 2021-09-06T02:54:04Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-04 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/103596 | - |
dc.description.abstract | Escherichia coli and Klebsiella pneumoniae are main pathogens in neutropenic fever even if the proportion of Gram-positive cocci is increasing. Extended-spectrum beta-lactamases (ESBL)-producing organisms are an emerging problem in nosocomial infection. Nevertheless, until now, information about risk factors for the acquisition and clinical outcomes of bacteremia due to ESBL-producing organisms is limited in neutropenic patients. From medical records collected between January 2007 and December 2008, we identified a total of 101 consecutive patients who developed bacteremia due to E. coli (n = 87) or K. pneumoniae (n = 14). Twenty-six (26 %) cases of bacteremia were caused by ESBL-producing organisms. A hospital stay of > 2 weeks during the 3 months preceding bacteremia [adjusted odds ratio (OR), 5.887; 95 % confidence interval (CI), 1.572-22.041] and the use of broad-spectrum cephalosporins in the 4 weeks prior to bacteremia (adjusted OR, 6.186; 95 % CI, 1.616-23.683) were significantly related to the acquisition of ESBL. Twenty-four (92 %) of the ESBL-producing organisms were susceptible to either piperacillin-tazobactam or amikacin. Aminoglycosides (amikacin or isepamicin) were the main appropriate antimicrobial agents used against the ESBL-producing isolates during the initial empirical treatment (16/22, 73 %). However, the 30-day mortality rates for ESBL bacteremia and non-ESBL bacteremia were not significantly different (15 vs 5 %; p = 0.199). As alternatives to carbapenem, piperacillin-tazobactam plus amikacin or isepamicin combinations may be effective empirical therapeutic options for patients with neutropenic fever who are at high risk of developing bacteremia with ESBL-producing pathogens. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | INFECTIOUS-DISEASES SOCIETY | - |
dc.subject | STEM-CELL TRANSPLANTATION | - |
dc.subject | RISK-FACTORS | - |
dc.subject | HEMATOLOGICAL MALIGNANCIES | - |
dc.subject | PIPERACILLIN-TAZOBACTAM | - |
dc.subject | INHIBITOR COMBINATIONS | - |
dc.subject | ANTIMICROBIAL AGENTS | - |
dc.subject | EMPIRICAL THERAPY | - |
dc.subject | CANCER-PATIENTS | - |
dc.subject | ENTEROBACTERIACEAE | - |
dc.title | Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Si-Hyun | - |
dc.identifier.doi | 10.1007/s00277-012-1631-y | - |
dc.identifier.scopusid | 2-s2.0-84877065762 | - |
dc.identifier.wosid | 000316015500014 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.92, no.4, pp.533 - 541 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 92 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 533 | - |
dc.citation.endPage | 541 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | INFECTIOUS-DISEASES SOCIETY | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | HEMATOLOGICAL MALIGNANCIES | - |
dc.subject.keywordPlus | PIPERACILLIN-TAZOBACTAM | - |
dc.subject.keywordPlus | INHIBITOR COMBINATIONS | - |
dc.subject.keywordPlus | ANTIMICROBIAL AGENTS | - |
dc.subject.keywordPlus | EMPIRICAL THERAPY | - |
dc.subject.keywordPlus | CANCER-PATIENTS | - |
dc.subject.keywordPlus | ENTEROBACTERIACEAE | - |
dc.subject.keywordAuthor | ESBL | - |
dc.subject.keywordAuthor | Escherichia | - |
dc.subject.keywordAuthor | Klebsiella | - |
dc.subject.keywordAuthor | Bacteremia | - |
dc.subject.keywordAuthor | Neutropenia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.